Policy
Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the biotech’s investigational COVID-19 and HIV drug, which artificially inflated its share price.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The winds of political change are blowing, and it’s not doing much to help investors. Pharmaceutical and biotech stocks were already suffering as the mid-term elections drew close.
Back in August, China’s Center for Drug Evaluation, its version of the U.S. Food and Drug Administration (FDA), fast-tracked 48 drugs that had already been approved in the U.S., Japan or Europe. These approvals reflect changes to China’s drug pharmaceutical environment.
The Centers for Medicare and Medicaid Services issues a number of proposals that could reduce the price of prescription drugs on Medicare plans.
The U.S. Food and Drug Administration (FDA) gave the green light late Monday to Bayer oncology drug Vitrakvi, a first-of-its-kind TRK inhibitor, after late-stage clinical trial results showed a 75 percent overall response rate and 22 percent complete response rate across various solid tumors.
Auris Medical Holding AG today announced the results of its pre-Investigational New Drug (pre-IND) meeting with the United States Food & Drug Administration (FDA), where the FDA addressed the Company’s questions and provided guidance on its AM-201 program with intranasal betahistine for the prevention of olanzapine-induced weight gain.
Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that the Drug Controller General in India (DCGI) has approved the company’s application to start a clinical Phase III study with PXL01 to prevent post-surgical adhesions after tendon repair surgery.
Event aimed at promoting a culture of innovation and to contribute in effort to achieve objectives of UAE national KPI on Cancer and cardio vascular diseases
Abu Dhabi based Maudsley Health, which is directly affiliated with the prestigious Maudsley Hospital in the UK, held their annual mental health conference under the patronage of H.E. Dr Yousif Al Serkal and the Ministry of Health and Prevention at the Al Amal Psychiatric Hospital, Dubai.
The campaign falls in line with the celebration of World Osteoporosis Day
As part of its strategy to provide the best electronic and smart services and enhance the quality of the healthcare system, the Ministry of Health and Prevention has launched an optional electronic service available on the website of the Ministry.